ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, confirmed that it has received an unsolicited preliminary non-binding proposal from Claritas Capital to acquire all of the outstanding shares of common stock of the Company, not already beneficially owned by Claritas and its affiliated funds, for cash consideration of between $1.35 and $1.80 per share. Consistent with its fiduciary duties, the Company's Board of Directors will carefully review Claritas’ proposal with the Board’s advisors and pursue the course of action it determines to be in the best interests of the Company and all of its stockholders.
Sharecare stockholders do not need to take any action at this time. There is no certainty that any transaction will be consummated, and Sharecare does not intend to comment further unless it determines that additional disclosure is appropriate. The proposal was required to be disclosed by Claritas under Regulation 13D by the U.S. Securities and Exchange Commission.
About Sharecare
Sharecare is the leading digital health company that helps people – no matter where they are in their health journey – unify and manage all their health in one place. Our comprehensive and data-driven virtual health platform is designed to help people, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by driving positive behavior change. Driven by our philosophy that we are all together better, at Sharecare, we are committed to supporting each individual through the lens of their personal health and making high-quality care more accessible and affordable for everyone. To learn more, visit www.sharecare.com.
Media Relations: This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.43 |
Daily Volume: | 0 |
Market Cap: | US$531.790M |
September 10, 2024 August 09, 2024 March 28, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load